217 related articles for article (PubMed ID: 10063968)
1. Schedule-dependent synergism and antagonism between paclitaxel and methotrexate in human carcinoma cell lines.
Kano Y; Akutsu M; Tsunoda S; Furuta M; Yazawa Y; Ando J
Oncol Res; 1998; 10(7):347-54. PubMed ID: 10063968
[TBL] [Abstract][Full Text] [Related]
2. Schedule-dependent synergism and antagonism between pemetrexed and paclitaxel in human carcinoma cell lines in vitro.
Kano Y; Akutsu M; Tsunoda S; Izumi T; Mori K; Fujii H; Yazawa Y; Mano H; Furukawa Y
Cancer Chemother Pharmacol; 2004 Dec; 54(6):505-13. PubMed ID: 15340759
[TBL] [Abstract][Full Text] [Related]
3. In vitro schedule-dependent interaction between paclitaxel and cisplatin in human carcinoma cell lines.
Kano Y; Akutsu M; Tsunoda S; Suzuki K; Yazawa Y
Cancer Chemother Pharmacol; 1996; 37(6):525-30. PubMed ID: 8612305
[TBL] [Abstract][Full Text] [Related]
4. Schedule-dependent interactions between vinorelbine and paclitaxel in human carcinoma cell lines in vitro.
Kano Y; Akutsu M; Suzuki K; Ando J; Tsunoda S
Breast Cancer Res Treat; 1999 Jul; 56(1):79-90. PubMed ID: 10517345
[TBL] [Abstract][Full Text] [Related]
5. Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro.
Kano Y; Akutsu M; Tsunoda S; Ando J; Matsui J; Suzuki K; Ikeda T; Inoue Y; Adachi K
Br J Cancer; 1996 Sep; 74(5):704-10. PubMed ID: 8795571
[TBL] [Abstract][Full Text] [Related]
6. Schedule-dependent interactions between paclitaxel and etoposide in human carcinoma cell lines in vitro.
Kano Y; Akutsu M; Suzuki K; Mori K; Yazawa Y; Tsunoda S
Cancer Chemother Pharmacol; 1999; 44(5):381-8. PubMed ID: 10501911
[TBL] [Abstract][Full Text] [Related]
7. Schedule-dependent synergism and antagonism between raltitrexed ("Tomudex") and methotrexate in human colon cancer cell lines in vitro.
Kano Y; Akutsu M; Tsunoda S; Suzuki K; Yazawa Y; Furukawa Y
Jpn J Cancer Res; 2001 Jan; 92(1):74-82. PubMed ID: 11173547
[TBL] [Abstract][Full Text] [Related]
8. In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines.
Kano Y; Akutsu M; Tsunoda S; Mori K; Suzuki K; Adachi KI
Cancer Chemother Pharmacol; 1998; 42(2):91-8. PubMed ID: 9654107
[TBL] [Abstract][Full Text] [Related]
9. Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic.
Vanhoefer U; Schleucher N; Klaassen U; Seeber S; Harstrick A
Semin Oncol; 2000 Feb; 27(1 Suppl 1):8-13. PubMed ID: 10697038
[TBL] [Abstract][Full Text] [Related]
10. Schedule-dependent interaction between paclitaxel and doxorubicin in human cancer cell lines in vitro.
Akutsu M; Kano Y; Tsunoda S; Suzuki K; Yazawa Y; Miura Y
Eur J Cancer; 1995 Dec; 31A(13-14):2341-6. PubMed ID: 8652267
[TBL] [Abstract][Full Text] [Related]
11. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G
Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
[TBL] [Abstract][Full Text] [Related]
12. Combinations of paclitaxel and etoposide in the treatment of lung cancer.
Perez EA; Buckwalter CA; Reid JP
Semin Oncol; 1996 Dec; 23(6 Suppl 15):21-5. PubMed ID: 8996593
[TBL] [Abstract][Full Text] [Related]
13. Sequence dependence of paclitaxel (Taxol) combined with cisplatin or alkylators in human cancer cells.
Liebmann JE; Fisher J; Teague D; Cook JA
Oncol Res; 1994; 6(1):25-31. PubMed ID: 7919549
[TBL] [Abstract][Full Text] [Related]
14. Schedule-dependent synergism and antagonism between pemetrexed and docetaxel in human lung cancer cell lines in vitro.
Kano Y; Tanaka M; Akutsu M; Mori K; Yazawa Y; Mano H; Furukawa Y
Cancer Chemother Pharmacol; 2009 Nov; 64(6):1129-37. PubMed ID: 19306094
[TBL] [Abstract][Full Text] [Related]
15. Schedule-dependent synergism of vinorelbine and 5-fluorouracil/UFT against non-small cell lung cancer.
Matsumoto S; Igishi T; Hashimoto K; Kodani M; Shigeoka Y; Nakanishi H; Touge H; Kurai J; Makino H; Takeda K; Yasuda K; Hitsuda Y; Shimizu E
Int J Oncol; 2004 Nov; 25(5):1311-8. PubMed ID: 15492820
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction.
Kohn EC; Reed E; Sarosy GA; Minasian L; Bauer KS; Bostick-Bruton F; Kulpa V; Fuse E; Tompkins A; Noone M; Goldspiel B; Pluda J; Figg WD; Liotta LA
Clin Cancer Res; 2001 Jun; 7(6):1600-9. PubMed ID: 11410496
[TBL] [Abstract][Full Text] [Related]
17. A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts.
Polizzi D; Pratesi G; Tortoreto M; Supino R; Riva A; Bombardelli E; Zunino F
Cancer Res; 1999 Mar; 59(5):1036-40. PubMed ID: 10070960
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel and radiotherapy: sequence-dependent efficacy--a preclinical model.
Niero A; Emiliani E; Monti G; Pironi F; Turci L; Valenti AM; Marangolo M
Clin Cancer Res; 1999 Aug; 5(8):2213-22. PubMed ID: 10473108
[TBL] [Abstract][Full Text] [Related]
19. Effect of selenium in combination with Adriamycin or Taxol on several different cancer cells.
Vadgama JV; Wu Y; Shen D; Hsia S; Block J
Anticancer Res; 2000; 20(3A):1391-414. PubMed ID: 10928049
[TBL] [Abstract][Full Text] [Related]
20. In vitro schedule-dependent interaction between paclitaxel and oxaliplatin in human cancer cell lines.
Tanaka R; Ariyama H; Qin B; Takii Y; Baba E; Mitsugi K; Harada M; Nakano S
Cancer Chemother Pharmacol; 2005 Jun; 55(6):595-601. PubMed ID: 15731917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
